Skip to main content

Table 1 Study characteristics

From: A systematic review of using and reporting survival analyses in acute lymphoblastic leukemia literature

Study

Sample size

Median Follow-up (months)

Outcome

Design

Allo-SCT

Non-allo-SCT

Attal [9]

41

64

30

DFS

Randomized trial

Bernasconi [10]

11

29

48

DFS

Clinical trial

Cornelissen [11]

96

161

65

OS, DFS

Clinical trial

De Witte [12]

30

33

60

OS, DFS

Clinical trial

Fielding [13]

81

77

98

OS, DFS

Clinical trial

Goldstone [14]

443

588

59

OS, DFS

Clinical trial

Hunault [15]

41

106

61

OS, DFS

Randomized¶ trial

Ifrah [16]

18

32

60

DFS

Clinical trial

Labar [17]

68

116

114

OS, DFS

Clinical trial

Ribera [18]

84

98

70

OS, DFS

Clinical trial

Sebban [19]

116

141

62

OS, DFS

Clinical trial

Thomas [21]

100

159

62

OS, DFS

Clinical trial

Takeuchi [20]

34

108

63

OS, DFS

Clinical trial

Ueda [22]

17

40

62

OS, DFS

Clinical trial

  1. Genetically randomization
  2. Abbreviation: Allo-SCT allogeneic-stem cell transplantation, DFS disease free survival, OS overall survival